32 128

Cited 0 times in

Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김승업-
dc.date.accessioned2022-08-23T00:09:48Z-
dc.date.available2022-08-23T00:09:48Z-
dc.date.issued2022-03-
dc.identifier.issn0815-9319-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189289-
dc.description.abstractLenvatinib is an oral multikinase inhibitor approved for use as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, like other agents in this drug class, lenvatinib is associated with clinically important adverse events (AEs) that could adversely affect patient outcomes. Hypertension, diarrhea, decreased appetite/weight, hand-foot skin reaction, and proteinuria are among the most common AEs associated with lenvatinib therapy. This article provides strategies for the effective management of lenvatinib-associated AEs based on the expert opinion of authors and currently available literature. Due to the high risk of AEs in patients receiving lenvatinib, prophylactic measures and regular monitoring for AEs are recommended. Lenvatinib dose interruption, adjustment, or discontinuation of treatment may be required for patients who develop AEs. For grade 1 or 2 AEs, dose interruption is generally not required. For persistent or intolerable grade 2 or 3 AEs, lenvatinib treatment should be interrupted until symptoms improve/resolve to grade 0-1 or baseline levels. Thereafter, treatment should be resumed at the same or a lower dose. Disease progression may occur in patients who do not initially respond to treatment or receive a suboptimal lenvatinib dose following dose reduction, resulting in lack of efficacy. Therefore, to derive maximum treatment benefit and ensure long-term disease control, lenvatinib should be maintained at the highest possible dose when managing AEs. To conclude, lenvatinib-associated AEs can be managed with prophylactic measures, regular monitoring and symptomatic management, which can ensure continued treatment and maximum survival benefit in patients with advanced HCC receiving first-line lenvatinib therapy.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular* / drug therapy-
dc.subject.MESHConsensus-
dc.subject.MESHDrug-Related Side Effects and Adverse Reactions* / therapy-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / drug therapy-
dc.subject.MESHPhenylurea Compounds* / adverse effects-
dc.subject.MESHProtein Kinase Inhibitors / adverse effects-
dc.subject.MESHQuinolines* / adverse effects-
dc.titleExpert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorBo Hyun Kim-
dc.contributor.googleauthorSu Jong Yu-
dc.contributor.googleauthorWonseok Kang-
dc.contributor.googleauthorSung Bum Cho-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorDo Young Kim-
dc.identifier.doi10.1111/jgh.15727-
dc.contributor.localIdA00385-
dc.contributor.localIdA00654-
dc.relation.journalcodeJ01417-
dc.identifier.eissn1440-1746-
dc.identifier.pmid34725855-
dc.subject.keywordadverse events-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordlenvatinib-
dc.subject.keywordmanagement-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김승업-
dc.citation.volume37-
dc.citation.number3-
dc.citation.startPage428-
dc.citation.endPage439-
dc.identifier.bibliographicCitationJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.37(3) : 428-439, 2022-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.